- Home
- KBON vs VALN Comparison
KBON vs VALN Comparison
Compare KBON & VALN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | KBON | VALN |
|---|---|---|
| Founded | 2025 | 2012 |
| Country | United States | France |
| Employees | N/A | N/A |
| Industry | Blank Checks | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 444.6M | 495.5M |
| IPO Year | N/A | 2021 |
Fundamental Metrics
Financial Performance| Metric | KBON | VALN |
|---|---|---|
| Price | $10.13 | $5.26 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $15.50 |
| AVG Volume (30 Days) | ★ 36.5K | 18.7K |
| Earning Date | 01-01-0001 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $93.87 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $10.04 | $5.04 |
| 52 Week High | $10.15 | $12.25 |
Technical Indicators
Market Signals| Indicator | KBON | VALN |
|---|---|---|
| Relative Strength Index (RSI) | 58.24 | 44.43 |
| Support Level | $10.05 | $5.10 |
| Resistance Level | $10.15 | $5.49 |
| Average True Range (ATR) | 0.02 | 0.19 |
| MACD | 0.00 | 0.03 |
| Stochastic Oscillator | 87.50 | 48.00 |
Price Performance
Historical ComparisonAbout KBON Karbon Capital Partners Corp. Class A Ordinary Shares
Karbon Capital Partners Corp is a blank check company.
About VALN Valneva SE
Valneva SE is a vaccine company focused on developing life-saving vaccines. Its portfolio includes three vaccines for travelers. The segments of the group are Commercialized vaccines which relate to marketed vaccines, the group's vaccines IXIARO/JESPECT, DUKORAL, IXCHIQ; Covid includes development, manufacturing, & distribution related to the COVID-19 vaccine, Vaccine candidates which relate to research and development programs to generate new approvable products to generate future cash flows from product sales through partnering with pharmaceutical companies; & Technologies and services which relate to services and inventions at a commercialization stage. The company generates majority of its revenue from product sales.